HRP20150937T1 - Pentaspecifiäśno protutijelo - Google Patents
Pentaspecifiäśno protutijelo Download PDFInfo
- Publication number
- HRP20150937T1 HRP20150937T1 HRP20150937TT HRP20150937T HRP20150937T1 HR P20150937 T1 HRP20150937 T1 HR P20150937T1 HR P20150937T T HRP20150937T T HR P20150937TT HR P20150937 T HRP20150937 T HR P20150937T HR P20150937 T1 HRP20150937 T1 HR P20150937T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- heavy
- sequences
- amino acid
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 10
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims 7
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 6
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims 6
- 108010014419 Chemokine CXCL1 Proteins 0.000 claims 6
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims 6
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 6
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- 241000699670 Mus sp. Species 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 238000002955 isolation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000012228 culture supernatant Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010062952 diffuse panbronchiolitis Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Claims (19)
1. Pentaspecifično protutijelo, naznačeno time što je specifično za i što neutralizira svakoje od ljudskog IL-8, Groα, Groβ, Groγ i ENA-78.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što se veže na ljudski IL-8, Groα, Groβ, Groγ i ENA-78 uz vrijednosti konstante ravnoteže, KD, manje od 10–7 M, 10–8 M ili 10–9 M, što je određeno rezonancijom površinskih plazmona.
3. Postupak dobivanja pentaspecifičnog protutijela, naznačen time što obuhvaća korake:
a. injiciranja u miša smjese ljudskog IL-8, Groα, Groβ, Groγ i ENA-78 u potpunom Freundovom adjuvansu (cFA);
b. injiciranja u miša smjese ljudskog IL-8, Groα, Groβ, Groγ i ENA-78 u nepotpunom Freundovom adjuvansu (iFA); i
c. injiciranja u miša smjese ljudskog IL-8, Groα, Groβ, Groγ i ENA-78, te kompleta od pet višestruko antigenih peptida (MAP), gdje svaka jedinica MAP ima po jedan zasebni slijed iz polipeptida s ID NO:49-53 u nepotpunom Freundovom adjuvansu;
d. izoliranja B-stanica iz miša;
e. fuzioniranja B-stanica sa stanicama mijeloma kako bi se dobilo besmrtne hibridomne stanice koje izlučuju željeno pentaspecifično protutijelo; i
f. izoliranja pentaspecifičnog protutijela iz supernatanta kulture hibridoma.
4. Postupak dobivanja pentaspecifičnog protutijela, naznačen time što obuhvaća korake:
a. injiciranja u miša kompleta od pet višestruko antigenih peptida (MAP), gdje svaka jedinica MAP ima po jedan zasebni slijed iz polipeptida s ID NO:49-53 (MAP komplet) u potpunom Freundovom adjuvansu;
b. injiciranja u miša MAP kompleta u nepotpunom Freundovom adjuvansu;
c. injiciranja u miša smjese svih ljudskih IL-8, Groα, Groβ, Groγ i ENA-78, te MAP kompleta u nepotpunom Freundovom adjuvansu;
d. izoliranja B-stanica iz miša; i
e. fuzioniranja B-stanica sa stanicama mijeloma kako bi se dobilo besmrtne hibridomne stanice koje izlučuju željeno pentaspecifično protutijelo; i
f. izoliranja pentaspecifičnog protutijela iz supernatanta kulture hibridoma.
5. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo sadrži:
a. varijabilna područja teškog i lakog lanca koja kodiraju nukleotidni sljedovi koji sadrže sljedove sa SEQ ID NO:1 odnosno SEQ ID NO:3;
b. varijabilna područja teškog i lakog lanca koja kodiraju nukleotidni sljedovi koji sadrže sljedove sa SEQ ID NO:5 odnosno SEQ ID NO:7;
c. varijabilno područje teškog lanca koje kodiraju nukleotidni sljedovi koji sadrže slijed sa SEQ ID NO:9;
d. teške i lake lance koje kodiraju nukleotidni sljedovi koji sadrže sljedove sa SEQ ID NO:11 odnosno SEQ ID NO:47, 59, 61 ili 63; ili
e. teške i lake lance koje kodiraju nukleotidni sljedovi koji sadrže sljedove koji su najmanje 90%, 95%, 98% ili 99% istovjetni sljedovima sa SEQ ID NO:11 odnosno SEQ ID NO:47, 59, 61 ili 63.
6. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo sadrži:
a. varijabilna područja teškog i lakog lanca koja sadrže aminokiselinske sljedove sa SEQ ID NO:2 odnosno SEQ ID NO:4;
b. varijabilna područja teškog i lakog lanca koja sadrže polipeptide koji su najmanje 90%, 95%, 98% ili 99% istovjetni aminokiselinskim sljedovima sa SEQ ID NO:2 odnosno SEQ ID NO:4;
c. varijabilna područja teškog i lakog lanca koja sadrže aminokiselinske sljedove sa SEQ ID NO:6 odnosno SEQ ID NO:8; ili
d. varijabilna područja teškog i lakog lanca koja sadrže polipeptide koji su najmanje 90%, 95%, 98% ili 99% istovjetni aminokiselinskim sljedovima sa SEQ ID NO:6 odnosno SEQ ID NO:8;
e. varijabilno područje teškog lanca koje sadrži aminokiselinski slijed sa SEQ ID NO:10, ili aminokiselinski slijed koji je najmanje 90%, 95%, 98% ili 99% istovjetan aminokiselinskom slijedu sa SEQ ID NO:10;
f. teške i lake lance koji sadrže aminokiselinske sljedove sa SEQ ID NO:46 odnosno SEQ ID NO:48, 60, 62 ili 64; ili
g. teške i lake lance koji sadrže polipeptide koji su najmanje 90%, 95%, 98% ili 99% istovjetni aminokiselinskim sljedovima sa SEQ ID NO:46 odnosno SEQ ID NO:48, 60, 62 ili 64.
7. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo sadrži najmanje jedno varijabilno područje koje se bira između (i) aminokiselinskog slijeda sa SEQ ID NO:2, 4, 6, 8 ili 10; ili (ii) aminokiselinskog slijeda koji je najmanje 90%, 95%, 98% ili 99% istovjetan bilo kojem od gore nabrojanih aminokiselinskih sljedova iz (i).
8. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo sadrži:
a. najmanje jedan CDR slijed koje se bira između SEQ ID NO:13, 14, 15, 16, 17 i 18;
b. najmanje jedan CDR slijed koje se bira između SEQ ID NO:19, 20, 21, 22, 23 i 24; ili
c. najmanje jedan CDR slijed koje se bira između SEQ ID NO:25, 26 i 27.
9. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo sadrži:
a. polipeptid sa SEQ ID NO:15;
b. polipeptid sa SEQ ID NO:21; ili
c. polipeptid sa SEQ ID NO:27.
10. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo sadrži:
a. najmanje četiri CDR slijeda koje se bira iz skupine koju čine SEQ ID NO:13, 14, 15, 16, 17 i 18; ili
b. najmanje četiri CDR slijeda koje se bira iz skupine koju čine: SEQ ID NO:19, 20, 21, 22, 23 i 24.
11. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo sadrži:
a. CDR sljedove sa SEQ ID NO:13, 14, 15, 16, 17 i 18;
b. varijabilna područja teškog i lakog lanca koja sadrže CDR sljedove sa SEQ ID NO:13, 14 i 15 odnosno SEQ ID NO:16, 17 i 18;
c. CDR sljedove sa SEQ ID NO:19, 20, 21, 22, 23 i 24;
d. varijabilna područja teškog i lakog lanca koja sadrže CDR sljedove sa SEQ ID NO:19, 20 i 21 odnosno SEQ ID NO:22, 23 i 24;
e. CDR sljedove sa SEQ ID NO:25, 26 i 27; ili
f. varijabilno područje teškog lanca koje sadrži aminokiselinske CDR sljedove sa SEQ ID NO:25, 26 i 27.
12. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što sadrži CDR sljedove sa SEQ ID NO:13, 14, 15, 16, 17 i 18.
13. Hibridom ili transfektom, naznačeni time što proizvode pentaspecifično protutijelo koje sadrži CDR sljedove sa:
a. SEQ ID NO:13, 14, 15, 16, 17 i 18;
b. SEQ ID NO:19, 20, 21, 22, 23 i 24; ili
c. SEQ ID NO:25, 26 i 27.
14. Rekombinantna eukariotska ili prokariotska stanica, naznačena time što proizvodi protutijelo koje sadrži:
a. CDR sljedove sa SEQ ID NO:13, 14, 15, 16, 17 i 18;
b. CDR sljedove sa SEQ ID NO:19, 20, 21, 22, 23 i 24;
c. CDR sljedove sa SEQ ID NO:25, 26 i 27;
d. teški i/ili laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:46 odnosno SEQ ID NO:48, 60, 62 ili 64; ili
e. teški i/ili laki lanac koji sadrži aminokiselinski slijed koji je najmanje 90%, 95%, 98% ili 99% istovjetan aminokiselinskom slijedu sa SEQ ID NO:46 odnosno SEQ ID NO:48, 60, 62 ili 64.
15. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što sadrži aminokiselinski sljedovi teškog i lakog lanca sa:
(a) SEQ ID NO:46 odnosno SEQ ID NO:48;
(b) SEQ ID NO:46 odnosno SEQ ID NO:62;
(c) SEQ ID NO:46 odnosno SEQ ID NO:60; ili
(d) SEQ ID NO:46 odnosno SEQ ID NO:64.
16. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo se veže unutar epitopa KELRCQCIKTYSKP (SEQ ID NO:54) ljudskog IL-8.
17. Farmaceutski pripravak, naznačen time što sadrži pentaspecifično protutijelo u skladu s bilo kojim od patentnih zahtjeva 1, 2, 5 do 12, ili 14 do 16, kao i farmaceutski prihvatljiv nosač.
18. Pentaspecifično protutijelo u skladu s bilo kojim od patentnih zahtjeva 1, 2, 5 do 12, 15 i 16, naznačeno time što je namijenjeno upotrebi u liječenju ili sprječavanju COPD, osteoartritisa, reumatoidnog artritisa, erozivnog artritisa, astme, ateroskleroze, upalne crijevne bolesti, psorijaze, odbacivanja presatka, gihta, raka, akutne plućne ozljede, akutne plućne bolesti, sepse, ARDS, bolesti perifernih arterija, sistemne skleroze, sindroma dišnog distresa kod novorođenčadi, pogoršanja astme i COPD, cistične fibroze, difuznog panbronhiolitisa, reperfuzijske ozljede i/ili endometrioze.
19. Postupak proizvodnje pentaspecifičnog protutijela (imunoglobulina) u istoj stanici domaćinu, naznačen time što obuhvaća korake:
(i) transformiranje navedene iste stanice domaćina
(a) prvim DNA slijedom koji u najmanju ruku kodira varijabilnu domenu teškog lanca imunoglobulina koji sadrži CDR domene sa SEQ ID NO:13, 14 i 15; i drugim DNA slijedom koji u najmanju ruku kodira varijabilnu domenu lakog lanca imunoglobulina koji sadrži CDR domene sa SEQ ID NO:16, 17 i 18;
(b) prvim DNA slijedom koji u najmanju ruku kodira varijabilnu domenu teškog lanca imunoglobulina koji sadrži CDR domene sa SEQ ID NO:19, 20 i 21; i drugim DNA slijedom koji u najmanju ruku kodira varijabilnu domenu lakog lanca imunoglobulina koji sadrži CDR domene sa SEQ ID NO:22, 23 i 24; ili
(c) prvim DNA slijedom koji kodira teški lanac koji sadrži polipeptid sa SEQ ID NO:46; i drugim DNA slijedom koji kodira laki lanac koji sadrži polipeptid sa SEQ ID NO:48, 60, 62 ili 64; i
(ii) eksprimiranje navedenog prvog DNA slijeda i navedenog drugog DNA slijed kako bi se proizvelo navedeni teški i laki lanac imunoglobulina kao zasebne molekule u navedenoj transformiranoj istoj stanici domaćinu.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91222907P | 2007-04-17 | 2007-04-17 | |
US4413208P | 2008-04-11 | 2008-04-11 | |
EP08745931.9A EP2146745B1 (en) | 2007-04-17 | 2008-04-16 | penta-specific antibody |
PCT/US2008/060424 WO2008130969A2 (en) | 2007-04-17 | 2008-04-16 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150937T1 true HRP20150937T1 (hr) | 2015-10-09 |
Family
ID=39872910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150937TT HRP20150937T1 (hr) | 2007-04-17 | 2015-09-07 | Pentaspecifiäśno protutijelo |
Country Status (30)
Country | Link |
---|---|
US (3) | US20080262203A1 (hr) |
EP (1) | EP2146745B1 (hr) |
JP (1) | JP5441885B2 (hr) |
KR (1) | KR101560841B1 (hr) |
CN (1) | CN101687035B (hr) |
AU (1) | AU2008243049B2 (hr) |
BR (1) | BRPI0810250A8 (hr) |
CA (1) | CA2684626C (hr) |
CL (1) | CL2008001071A1 (hr) |
CO (1) | CO6251323A2 (hr) |
CR (1) | CR11116A (hr) |
CY (1) | CY1116671T1 (hr) |
DK (1) | DK2146745T3 (hr) |
DO (1) | DOP2009000236A (hr) |
EA (1) | EA024621B1 (hr) |
ES (1) | ES2547475T3 (hr) |
HK (1) | HK1136970A1 (hr) |
HR (1) | HRP20150937T1 (hr) |
HU (1) | HUE027584T2 (hr) |
IL (1) | IL201440A (hr) |
MA (1) | MA31310B1 (hr) |
MX (1) | MX2009011153A (hr) |
MY (1) | MY150525A (hr) |
NZ (1) | NZ580239A (hr) |
PE (1) | PE20090302A1 (hr) |
PL (1) | PL2146745T3 (hr) |
PT (1) | PT2146745E (hr) |
SI (1) | SI2146745T1 (hr) |
TW (1) | TWI473815B (hr) |
WO (1) | WO2008130969A2 (hr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
CA2783563A1 (en) * | 2009-12-07 | 2011-06-16 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
US20120315267A1 (en) * | 2010-02-09 | 2012-12-13 | Glaxosmithkline Llc | Novel uses |
TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
WO2013166099A1 (en) * | 2012-05-01 | 2013-11-07 | Glaxosmithkline Llc | Novel antibodies |
WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
CN113831406A (zh) | 2012-08-24 | 2021-12-24 | 中外制药株式会社 | FcγRIIb特异性Fc区变体 |
EP2970445A4 (en) | 2013-03-12 | 2017-02-22 | Decimmune Therapeutics Inc. | Humanized anti-n2 antibodies |
US9290570B2 (en) | 2013-03-15 | 2016-03-22 | Eli Lilly And Company | Pan-ELR+ CXC Chemokine Antibodies |
JO3580B1 (ar) | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
EP2796875B8 (en) * | 2013-04-23 | 2020-11-25 | Albert-Ludwigs-Universität Freiburg | Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis |
KR20160021125A (ko) * | 2013-05-17 | 2016-02-24 | 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스) | 항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도 |
PE20171111A1 (es) | 2014-12-19 | 2017-08-07 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2018025982A1 (ja) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Il-8関連疾患の治療用又は予防用組成物 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
WO2019036605A2 (en) * | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF |
EP3694545A4 (en) | 2017-10-11 | 2021-12-01 | Board Of Regents, The University Of Texas System | HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM |
CN116327926A (zh) | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
AU2019239568A1 (en) * | 2018-03-23 | 2020-09-17 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor |
WO2021113697A1 (en) * | 2019-12-05 | 2021-06-10 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates |
US20220080044A1 (en) * | 2020-09-14 | 2022-03-17 | National Yang-Ming University | Method for preventing or treating peripheral arterial occlusive disease |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE913192A1 (en) * | 1990-09-12 | 1992-02-25 | Scripps Research Inst | Active site of interleukin-8: polypeptide analogs and¹antibodies |
US6448379B1 (en) * | 1993-09-14 | 2002-09-10 | Chiron Corporation | IL8 inhibitors |
JP4423680B2 (ja) * | 1995-06-07 | 2010-03-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Cdr−グラフト化抗組織因子抗体及びその使用 |
GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
AR030753A1 (es) * | 2000-09-25 | 2003-09-03 | Smithkline Beecham Corp | Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas |
CZ20031307A3 (cs) * | 2000-10-13 | 2003-10-15 | Biogen, Inc. | Humanizované protilátky k lymfotoxinovému beta receptoru |
AU2002257567A1 (en) | 2001-04-26 | 2002-11-11 | Dakocytomation Denmark A/S | Pan-specific monoclonal antibody |
US20040022726A1 (en) * | 2002-06-03 | 2004-02-05 | Goldenberg David M. | Methods and compositions for intravesical therapy of bladder cancer |
JP4739763B2 (ja) * | 2002-12-16 | 2011-08-03 | ゲンマブ エー/エス | インターロイキン8(il−8)に対するヒトモノクローナル抗体 |
AU2003303543A1 (en) * | 2002-12-26 | 2004-07-29 | Chugai Seiyaku Kabushiki Kaisha | Agonist antibody against heteroreceptor |
WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
US20110129412A1 (en) * | 2005-06-02 | 2011-06-02 | Astrazeneca Ab | Antibodies Directed to CD20 and Uses Thereof |
CA2678008C (en) * | 2005-06-17 | 2013-07-30 | Imclone Systems Incorporated | Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
WO2007056411A2 (en) * | 2005-11-08 | 2007-05-18 | Genentech, Inc. | Method of producing pan-specific antibodies |
US8454960B2 (en) * | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
-
2008
- 2008-04-15 CL CL2008001071A patent/CL2008001071A1/es unknown
- 2008-04-16 TW TW97113788A patent/TWI473815B/zh not_active IP Right Cessation
- 2008-04-16 US US12/103,761 patent/US20080262203A1/en not_active Abandoned
- 2008-04-16 JP JP2010504204A patent/JP5441885B2/ja not_active Expired - Fee Related
- 2008-04-16 DK DK08745931.9T patent/DK2146745T3/en active
- 2008-04-16 MY MYPI20094336 patent/MY150525A/en unknown
- 2008-04-16 US US12/596,262 patent/US8496932B2/en not_active Expired - Fee Related
- 2008-04-16 AU AU2008243049A patent/AU2008243049B2/en not_active Ceased
- 2008-04-16 PE PE2008000664A patent/PE20090302A1/es not_active Application Discontinuation
- 2008-04-16 NZ NZ580239A patent/NZ580239A/en not_active IP Right Cessation
- 2008-04-16 BR BRPI0810250A patent/BRPI0810250A8/pt not_active Application Discontinuation
- 2008-04-16 HU HUE08745931A patent/HUE027584T2/en unknown
- 2008-04-16 KR KR1020097023814A patent/KR101560841B1/ko active IP Right Grant
- 2008-04-16 ES ES08745931.9T patent/ES2547475T3/es active Active
- 2008-04-16 CA CA2684626A patent/CA2684626C/en not_active Expired - Fee Related
- 2008-04-16 MX MX2009011153A patent/MX2009011153A/es active IP Right Grant
- 2008-04-16 EP EP08745931.9A patent/EP2146745B1/en not_active Not-in-force
- 2008-04-16 PT PT87459319T patent/PT2146745E/pt unknown
- 2008-04-16 WO PCT/US2008/060424 patent/WO2008130969A2/en active Application Filing
- 2008-04-16 SI SI200831489T patent/SI2146745T1/sl unknown
- 2008-04-16 EA EA200970954A patent/EA024621B1/ru not_active IP Right Cessation
- 2008-04-16 PL PL08745931T patent/PL2146745T3/pl unknown
- 2008-04-16 CN CN2008800205593A patent/CN101687035B/zh not_active Expired - Fee Related
-
2009
- 2009-10-08 DO DO2009000236A patent/DOP2009000236A/es unknown
- 2009-10-11 IL IL201440A patent/IL201440A/en not_active IP Right Cessation
- 2009-10-15 MA MA32279A patent/MA31310B1/fr unknown
- 2009-10-19 CO CO09116578A patent/CO6251323A2/es active IP Right Grant
- 2009-11-17 CR CR11116A patent/CR11116A/es unknown
-
2010
- 2010-05-14 HK HK10104687.8A patent/HK1136970A1/xx not_active IP Right Cessation
-
2013
- 2013-06-26 US US13/927,352 patent/US8828384B2/en not_active Expired - Fee Related
-
2015
- 2015-09-01 CY CY20151100768T patent/CY1116671T1/el unknown
- 2015-09-07 HR HRP20150937TT patent/HRP20150937T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150937T1 (hr) | Pentaspecifiäśno protutijelo | |
HRP20180320T1 (hr) | Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba | |
ES2609439T3 (es) | Humanización rápida de anticuerpos | |
CN103261220B (zh) | 用于生成多特异性和多价抗体的方法 | |
HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
CN104302169B (zh) | 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物 | |
JP2013539369A5 (hr) | ||
HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
RU2006127314A (ru) | Вакцина, стимулирующая рост, основанная на нейтрализующем эпитопе | |
HRP20231410T1 (hr) | Konstrukti bispecifičnih antitijela koji vežu mezotelin i cd3 | |
HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
AU2020400030A1 (en) | Variant nucleic acid libraries for adenosine receptors | |
JP2009517405A5 (hr) | ||
JP2011526480A5 (hr) | ||
HRP20231264T1 (hr) | Protutijela protiv csf-1r | |
AU2017428737B2 (en) | Dynamic human heavy chain antibody libraries | |
JP2020510659A5 (hr) | ||
JP2022033762A (ja) | ダイナミックヒト抗体軽鎖ライブラリー | |
JP2022513043A (ja) | 操作されたcd25ポリペプチドおよびその使用 | |
WO2023023183A2 (en) | Sars-cov-2 antibodies and related compositions and methods of use | |
HRP20220884T1 (hr) | Proteini specifični za baff i b7rp1 i njihova uporaba | |
KR20210013000A (ko) | Sftsv에 결합 가능한 나노 항체 및 이의 응용 | |
CN107964045B (zh) | 一种人鼠嵌合抗CXCR2全分子IgG及其应用 | |
CN107207581A (zh) | 用于制备优化的治疗分子的方法 |